From GlobeNewswire: 2025-03-31 09:00:00

Traws Pharma’s tivoxavir marboxil shows significant antiviral activity in animal models and positive Phase 1 data for bird flu treatment. Ongoing FDA discussions aim for accelerated approval under the “Animal Rule.” Cash Runway supports operations into Q1 2026. Investor Update call scheduled for March 31, 2025, at 10:00 AM ET.

Recent studies demonstrate Traws Pharma’s tivoxavir marboxil’s effectiveness against bird flu in non-human primates. Positive data presented at ICAR. Phase I studies show tivoxavir marboxil’s potential as a single-dose therapy for H5N1 bird flu. Ratutrelvir also shows promise as a COVID-19 treatment. CEO Werner Cautreels to retire.

Financial results show Traws Pharma has cash, cash equivalents, and short-term investments totaling approximately $21.3 million as of December 31, 2024. R&D expenses increased to $12.8 million, G&A expenses increased to $12.3 million. Net loss for 2024 was $166.5 million, with 5,073,790 shares outstanding as of March 26, 2025.

Tivoxavir marboxil is an investigational single-dose treatment for bird flu and seasonal influenza, with potential for significant market opportunity. Ratutrelvir is a potential COVID-19 treatment that may reduce clinical rebound and long COVID risk. Both candidates have shown promising preclinical and Phase 1 data.

Traws Pharma is a biopharmaceutical company focusing on respiratory viral diseases. Developing novel antiviral agents with accelerated clinical trial strategies. Lead programs target bird flu and COVID-19. Tivoxavir marboxil and ratutrelvir show promise in preclinical and Phase 1 studies. Company aims for patient safety and simplicity in dosing.

(Source: https://www.globenewswire.com/news-release/2025/03/31/2424671/0/en/Traws-Pharma-Reports-2024-Financial-Results-and-Recent-Business-Highlights.html)



Read more at GlobeNewswire:: Traws Pharma Reports Full Year 2024 Results and Business